|
|
|
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
| Center | Date | Time | Location* |
|---|---|---|---|
| CBER | March 17, 2004 | 1 p.m. - 5 p.m. | Food and Drug
Administration |
| * This meeting will be held by a telephone conference call. The public is welcome to attend the meeting at the location shown above. A speaker telephone will be provided at the specified location for public participation in this meeting. | |||
Agenda:
This committee will discuss recommendations pertaining to the influenza virus
vaccine formulation.
Background material and meeting information will become available no later than the day before the meeting (Simply select the appropriate committee link).
Procedure:
On March 17, 2004, from 1 p.m. to 5 p.m., the meeting is open to the public.
Interested persons may present data, information, or views, orally or in writing,
on issues pending before the committee. Written submissions may be made to the
contact person by March 11, 2004. Oral presentations from the public will be
scheduled between approximately 2 p.m. and 3 p.m. Time allotted for each presentation
may be limited. Those desiring to make formal oral presentations should notify
the contact person before March 11, 2004, and submit a brief statement of the
general nature of the evidence or arguments they wish to present, the names
and addresses of proposed participants, and an indication of the approximate
time requested to make their presentation. Persons attending FDA's advisory
committee meetings are advised that the agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings
and will make every effort to accommodate persons with physical disabilities
or special needs. If you require special accommodations due to a disability,
please contact William Freas or Denise H. Royster at at least 7 days in advance
of the meeting.
Contact Person:
William Freas or Denise H. Royster, Food and Drug Administration,
Center for Biologics Evaluations and Research (HFM–71), 1401 Rockville
Pike, Rockville, MD, 20852, 301–827–0314, or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area),
code3014512391. Please call the Information Line for up-to-date information
on this meeting.
[ Full FR Notice ]